2022. Immunogenicity of Guselkumab (GUS) Among Psoriasis Patients in VOYAGE (VOY) 1&2 Studies. SKIN The Journal of Cutaneous Medicine. 6, 2 (Mar. 2022), s11. DOI:https://doi.org/10.25251/skin.6.supp.11.